All In MedTech

FDA Clearance Tracker · P220034

LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Mar 29, 2024 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Mar 29, 2024

Approved

Time to decision

458 days

Received Dec 27, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P220034
Device name
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
Applicant location
Stillwater, MN
Received
Dec 27, 2022
Decided
Mar 29, 2024
Decision
Approved
Supplements
10 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MYL

FDA's approval statement

As written in FDA's record.

Approval for LIAISON Biotrin Parvovirus B19 IgG Plus and LIAISON Biotrin Control Parvovirus B19 IgG Plus. The LIAISON Biotrin Parvovirus B19 IgG Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgG antibodies to B19 virus (B19V, previously known as human parvovirus B19) in human serum, lithium heparin, dipotassium EDTA (K2-EDTA), and sodium citrated plasma. The test may be used for testing women of childbearing age where there is a suspicion of exposure to human B19V. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MYL. The earliest in FDA's data is P970054, decided Aug 6, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for DiaSorin, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.